C
Chloe Orkin
Researcher at Queen Mary University of London
Publications - 229
Citations - 14129
Chloe Orkin is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Viral load & Medicine. The author has an hindex of 48, co-authored 202 publications receiving 11614 citations. Previous affiliations of Chloe Orkin include Barts Health NHS Trust & St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
Silvia Montoto,Jamie Wilson,Kate Shaw,Maureen Heath,Andrew D. Wilson,Christopher McNamara,Chloe Orkin,Mark T. Nelson,Margaret A. Johnson,Mark Bower,Kate Cwynarski +10 more
TL;DR: The intensive regimen CODOX-M/IVAC, a feasible and effective chemotherapy, is associated with an excellent immunological recovery in patients with HIV-BL on HAART.
Journal ArticleDOI
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes
J Turner,Loveleen Bansi,RJ Gilson,Brian Gazzard,John Walsh,Deenan Pillay,Chloe Orkin,Ashley S. Phillips,Philippa Easterbrook,Melanie S. Johnson,Kholoud Porter,Achim Schwenk,Teresa Hill,Clifford Leen,Jane Anderson,M Fisher,Caroline A. Sabin +16 more
TL;DR: HCV infection had no impact on HIV virological outcomes or immunological response to HIV treatment, and the long‐term impact on morbidity and mortality remain to be determined.
Journal ArticleDOI
HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era.
Rita Coutinho,Alessia Dalla Pria,Shreyans Gandhi,Katharine Bailey,Paul Fields,Kate Cwynarski,Andrew D. Wilson,Panagiotis Papanastasopoulos,Melinda Tenant-Flowers,Andrew J. Webb,Fiona Burns,Robert Marcus,Chloe Orkin,Silvia Montoto,Mark Bower +14 more
TL;DR: HIV-positive patients diagnosed with DLBCL in the cART era have an excellent outcome when treated with standard immunochemotherapy, and the choice of chemotherapy in patients with lymphoma should not be influenced by HIV status.
Journal ArticleDOI
Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign.
Chloe Orkin,S. Flanagan,E Wallis,Georgina Ireland,Rageshri Dhairyawan,J. Fox,R. Nandwani,Rebecca O'Connell,Monica Lascar,J. Bulman,Iain Reeves,Adrian Palfreeman,Graham R. Foster,K Ahmad,Jane Anderson,C. Y. W. Tong,S. Lattimore +16 more
TL;DR: This study investigated the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) during a routine testing pilot in UK Emergency Departments (EDs).
Journal ArticleDOI
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study
RJ Gilson,S-L Man,Andrew Copas,A Rider,S Forsyth,Teresa Hill,Loveleen Bansi,Kholoud Porter,Brian Gazzard,Chloe Orkin,Deenan Pillay,Achim Schwenk,Melanie S. Johnson,P Easterbook,John Walsh,M Fisher,Clifford Leen,Jane Anderson,Caroline A. Sabin +18 more
TL;DR: Patients starting highly active antiretroviral therapy (HAART) may have a suboptimal CD4 increase despite rapid virological suppression, and the frequency and the significance for patient care of this discordant response are uncertain.